Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SK Bio To Go All The Way With Novel Epilepsy Drug

This article was originally published in PharmAsia News

Executive Summary

SK Biopharmaceuticals, the new drug development subsidiary of South Korean conglomerate SK Group, is to seek approval of epilepsy drug YKP3089 without conducting a Phase III efficacy trial and aims to launch the drug globally in 2018, becoming the first domestic pharma to develop, commercialize and market a new product single handedly.

You may also be interested in...



Committing To Drug Development In World's Biggest Market: SK's Story

South Korean companies are seeking diverse ways to enter global drug markets, and SK Biopharmaceuticals is leading the way by establishing physical R&D and commercial operations in the US to progress its CNS drug pipeline. Executives of SK Life Science, the US subsidiary of SK Biopharmaceuticals, talk to Scrip about why they are committed to developing drugs in the US and what advantages and challenges they have by establishing a footprint in this key market.

Incentives, Novel Tech Seen Driving Multiple Korean IPOs In 2018

Despite an expected absence of large floats like that of Celltrion Healthcare last year, IPOs by biotech and pharma firms in South Korea are poised to rise in 2018 amid an improved stock listing environment and progress in novel drug development.

LG Restructuring Ups Group Emphasis On ‘Red Biotech’

LG's decision to merge its biopharma affiliate LG Life Sciences with the group's main cash cow, LG Chem, signals a focus on "red biotech" and a desire to keep up with other major South Korean conglomerates such as Samsung that are building their biopharma businesses. LG plans to sharply hike sector R&D and capital investments to position the combined operation as a future growth engine.

Topics

Related Companies

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel